Treatment of psoriasis with deucravacitinib

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effects of deucravacitinib, a TYK2 inhibitor, on immune cell function in patients with moderate to severe psoriasis. It is a one-arm, open-label study involving 25 participants who will undergo biopsy and blood sampling before and during treatment. The goal is to analyze the molecular profiles of immune cells to determine how deucravacitinib alters psoriatic signatures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA \>= 10%, PASI \>=12, static Physician's Global Assessment (sPGA) 3 and above)

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Raymond Cho, MD, PhD — University of California, San Francisco
• Study coordinator: Raymond Cho, MD, PhD
• Email: rashes@ucsf.edu
• Phone: 415 575 0524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HRS-4139 safety and pharmacology in healthy adults

  This early-phase study tests a single dose of HRS-4139 to see if it is safe and how the body handles it in healthy adults aged 18–55.

  Recruiting Phase 1 Fujian Shengdi Pharmaceutical Co., Ltd. · Changsha, Hunan · NCT07802964

• Deucravacitinib for scarring hair loss (frontal fibrosing and central centrifugal alopecia)

  This trial will test whether taking deucravacitinib once daily for 48 weeks helps adults with frontal fibrosing alopecia or central centrifugal cicatricial alopecia.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07508488

• Total Coumarin botanical cream for psoriasis vulgaris

  This trial will try a botanical Total Coumarin cream applied twice daily for 8 weeks to see if it helps adults with mild to moderate psoriasis.

  Recruiting Phase 3 Psoriasis Research Institute of Guangzhou · New York, New York · NCT07426120

• Topical diacerein in plaque psoriasis (adult) explores if a cream helps skin improve

  This trial tests whether applying a topical diacerein cream twice daily for 8 weeks helps adults with mild-to-moderate psoriasis vulgaris improve symptoms more than a placebo.

  Recruiting Phase 4 Cairo University · Cairo · NCT07352306

• Vaspin gene changes and blood vaspin levels in people with psoriasis

  This test will see if specific vaspin gene variants are linked to blood vaspin levels in people with psoriasis.

  Recruiting Aswan University · Aswān · NCT07320872

• Deucravacitinib added to current PsA treatment for difficult-to-control disease

  This study tests whether adding deucravacitinib to a patient’s existing Psoriatic Arthritis treatment can improve symptoms and quality of life for adults with hard-to-control disease.

  Recruiting Phase 4 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07280702

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.